Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles 2023-11, Vol.28 (47), p.1
Hauptverfasser: Rose, Angela Mc, Nicolay, Nathalie, Sandonis Martín, Virginia, Mazagatos, Clara, Petrović, Goranka, Baruch, Joaquin, Denayer, Sarah, Seyler, Lucie, Domegan, Lisa, Launay, Odile, Machado, Ausenda, Burgui, Cristina, Vaikutyte, Roberta, Niessen, F Annabel, Loghin, Isabela I, Husa, Petr, Aouali, Nassera, Panagiotakopoulos, George, Tolksdorf, Kristin, Horváth, Judit Krisztina, Howard, Jennifer, Pozo, Francisco, Gallardo, Virtudes, Nonković, Diana, Džiugytė, Aušra, Bossuyt, Nathalie, Demuyser, Thomas, Duffy, Róisín, Luong Nguyen, Liem Binh, Kislaya, Irina, Martínez-Baz, Iván, Gefenaite, Giedre, Knol, Mirjam J, Popescu, Corneliu, Součková, Lenka, Simon, Marc, Michelaki, Stella, Reiche, Janine, Ferenczi, Annamária, Delgado-Sanz, Concepción, Lovrić Makarić, Zvjezdana, Cauchi, John Paul, Barbezange, Cyril, Van Nedervelde, Els, O'Donnell, Joan, Durier, Christine, Guiomar, Raquel, Castilla, Jesús, Jonikaite, Indrė, Bruijning-Verhagen, Patricia Cjl, Lazar, Mihaela, Demlová, Regina, Wirtz, Gil, Amerali, Marina, Dürrwald, Ralf, Kunstár, Mihály Pál, Kissling, Esther, Bacci, Sabrina, Valenciano, Marta
Format: Artikel
Sprache:eng
Schlagworte:
Adult
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Europe - epidemiology
Hospitalization
Humans
Immunization
Immunology
Life Sciences
Pneumonia
RNA, Messenger
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccine Efficacy
Vaccinology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received 
ISSN:1560-7917
1025-496X
1560-7917
1025-496X
DOI:10.2807/1560-7917.ES.2023.28.47.2300187